Orenstein Susan R, Shalaby Theresa M, Kelsey Sheryl F, Frankel Eric
Pediatric Gastroenterology, University of Pittsburgh School of Medicine, Children's Hospital of Pittsburgh, One Children's Place, Pittsburgh, PA 15213-2583, USA.
Am J Gastroenterol. 2006 Mar;101(3):628-40. doi: 10.1111/j.1572-0241.2006.00442.x.
To determine the natural history of infant gastroesophageal reflux disease (GERD) with esophagitis, we periodically analyzed symptoms and biopsies during 1 yr in 19 infants randomly assigned to placebo in a pharmacotherapy study.
One hundred infants who were referred during 1994-1999 for GERD, were unresponsive to 2-wk life-style measures, and manifested morphometric reflux esophagitis, were assigned at random to one of four treatment arms. This analysis examines the 19 (ages 2.8-6.0 months) assigned to placebo who returned for initial follow-up. SYMPTOMS and esophageal biopsy were assessed at baseline and 2, 4, 6, and 12 months. At any visit with both symptoms and biopsy unimproved, infants were "rescued" to open label active drug.
By 12 months, 10/19 completed without rescue; the 9 others withdrew (3) or required pharmacotherapy (6).
Among the 10 nonrescued completers, parents' global score rated 9 "completely well," and 1 "improved." Comparing 12-month symptoms to baseline symptoms in the 10 completers, fewer reported regurgitation >3/day, >1 Tbsp, or that was uncomfortable; crying >1 h/d, or during or after feeds; or arching spells or abnormal hiccups (p < 0.05, chi(2)). Biopsy: None of the 10 ever had normal biopsies (basal cell layer <25% and papillary height <53% of epithelial thickness). One had normal papillary height, but abnormal basal thickness. Five others had normal basal thickness, but all five of them had abnormal papillary height.
Although symptoms improved in more than half of the infants with reflux esophagitis followed longitudinally for 1 yr without pharmacotherapy, histology remained abnormal.
为了确定患有食管炎的婴儿胃食管反流病(GERD)的自然病史,我们在一项药物治疗研究中,对随机分配到安慰剂组的19名婴儿进行了为期1年的症状和活检定期分析。
1994年至1999年间因GERD前来就诊、对为期2周的生活方式调整措施无反应且表现出形态学反流性食管炎的100名婴儿,被随机分配到四个治疗组之一。本分析研究了被分配到安慰剂组且返回进行首次随访的19名婴儿(年龄2.8 - 6.0个月)。在基线、2、4、6和12个月时评估症状和食管活检情况。在任何一次症状和活检均无改善的就诊时,婴儿会“接受挽救性治疗”,改用开放标签的活性药物。
到12个月时,19名婴儿中有10名未接受挽救性治疗即完成研究;另外9名退出研究(3名)或需要药物治疗(6名)。
在10名未接受挽救性治疗的完成研究的婴儿中,家长的总体评分显示9名“完全康复”,1名“有所改善”。将10名完成研究的婴儿12个月时的症状与基线症状进行比较,报告反流>3次/天、>1汤匙或反流时不适的情况减少;哭闹>1小时/天、或在喂食期间或之后哭闹的情况减少;或弓背发作或异常打嗝的情况减少(p<0.05,卡方检验)。活检:10名婴儿中没有一人活检结果正常(基底细胞层<上皮厚度的25%且乳头高度<上皮厚度的53%)。1名婴儿乳头高度正常,但基底厚度异常。另外5名婴儿基底厚度正常,但他们5人的乳头高度均异常。
尽管超过一半患有反流性食管炎的婴儿在未接受药物治疗的情况下纵向随访1年症状有所改善,但组织学检查仍显示异常。